PepGen Inc. (PEPG) Stock Ticker
PEPG right now
Market factors today
Unlock the full PEPG picture
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
PEPG stock facts
| Ticker symbol | PEPG |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $179.1M |
| CEO | James McArthur |
| Employees | 57 |
| Headquarters | Boston, MA, US |
| IPO date | 2022-05-06 |
| Website | www.pepgen.com |
What you can see for PEPG on Tickr
Live PEPG price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PEPG report.
Rankings
FAQ
What is the ticker symbol for PepGen Inc.?
The ticker symbol for PepGen Inc. is PEPG, listed on the NASDAQ.
What is PEPG?
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the…